Both Danger Mouse and DavidLynch join World Cafe host David Dye for an interview about the storied album, its creative process and their late collaborator.
In a Sept. 23 note to investors, Merrill Lynch analyst David W. Munno, who covers antibiotic maker Cubist , a Vicuron competitor, wrote that he suspected Pfizer had received an approvable letter.